MURA insider transaction filings
Mural Oncology plc — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-12-05. Screen MURA transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for MURA between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Mural Oncology plc
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-12-05 | 4 | Loew Caroline — Chief Executive Officer, Director | Disposition to issuer (D): 293,059 · Disposition to issuer (D): 379,690 (derivative) · Disposition to issuer (D): 90,025 (derivative) · Disposition to issuer (D): 134,225 (derivative) | EDGAR |
| 2025-12-05 | 4 | Goodman Vicki L — Chief Medical Officer | Disposition to issuer (D): 84,727 · Disposition to issuer (D): 135,604 (derivative) · Disposition to issuer (D): 65,000 (derivative) | EDGAR |
| 2025-12-05 | 4 | Minegishi Sachiyo — Director | Disposition to issuer (D): 8,637 (derivative) · Disposition to issuer (D): 15,335 (derivative) | EDGAR |
| 2025-12-05 | 4 | Hickey Benjamin — Director | Disposition to issuer (D): 8,637 (derivative) · Disposition to issuer (D): 8,462 (derivative) · Disposition to issuer (D): 15,021 (derivative) | EDGAR |
| 2025-12-05 | 4 | Cutler Adam D. — Chief Financial Officer | Disposition to issuer (D): 99,290 · Disposition to issuer (D): 146,452 (derivative) · Disposition to issuer (D): 65,000 (derivative) | EDGAR |
| 2025-12-05 | 4 | Keson-Brookes Maiken — Chief Legal Officer | Disposition to issuer (D): 68,834 · Disposition to issuer (D): 54,242 (derivative) · Disposition to issuer (D): 31,200 (derivative) · Disposition to issuer (D): 65,000 (derivative) | EDGAR |
| 2025-12-05 | 4 | Golumbeski George — Director | Disposition to issuer (D): 8,637 (derivative) · Disposition to issuer (D): 15,334 (derivative) | EDGAR |
| 2025-12-05 | 4 | Jackson Scott Thomas — Director | Disposition to issuer (D): 8,637 (derivative) · Disposition to issuer (D): 8,462 (derivative) · Disposition to issuer (D): 15,021 (derivative) | EDGAR |
| 2025-12-05 | 4 | Cuss Francis M — Director | Disposition to issuer (D): 8,637 (derivative) · Disposition to issuer (D): 8,462 (derivative) · Disposition to issuer (D): 15,021 (derivative) | EDGAR |
| 2025-11-10 | 4 | Goodman Vicki L — Chief Medical Officer | Sale (S): 5,036 @ $2.08 | EDGAR |
| 2025-11-10 | 4 | Cutler Adam D. — Chief Financial Officer | Sale (S): 7,148 @ $2.09 | EDGAR |
| 2025-07-23 | 4 | Keson-Brookes Maiken — See Remarks | Sale (S): 2,572 @ $2.48 | EDGAR |
| 2025-07-22 | 4 | Keson-Brookes Maiken — See Remarks | Sale (S): 2,158 @ $2.48 | EDGAR |
| 2025-07-09 | 4 | Loew Caroline — Chief Executive Officer, Director | Sale (S): 12,531 @ $2.43 | EDGAR |
| 2025-06-13 | 4 | Minegishi Sachiyo — Director | Grant/award (A): 8,637 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Hickey Benjamin — Director | Grant/award (A): 8,637 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Golumbeski George — Director | Grant/award (A): 8,637 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Jackson Scott Thomas — Director | Grant/award (A): 8,637 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Cuss Francis M — Director | Grant/award (A): 8,637 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Loew Caroline — Chief Executive Officer, Director | Grant/award (A): 72,275 @ $0 · Sale (S): 4,313 @ $3.36 · Grant/award (A): 134,225 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Goodman Vicki L — Chief Medical Officer | Grant/award (A): 35,000 @ $0 · Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Cutler Adam D. — Chief Financial Officer | Grant/award (A): 35,000 @ $0 · Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Keson-Brookes Maiken — See Remarks | Grant/award (A): 35,000 @ $0 · Sale (S): 1,262 @ $3.36 · Sale (S): 1,469 @ $3.45 · Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2025-02-25 | 4 | Goodman Vicki L — Chief Medical Officer | Sale (S): 13,186 @ $3.89 | EDGAR |
| 2024-12-26 | 4 | Keson-Brookes Maiken — See Remarks | Sale (S): 2,555 @ $3.27 | EDGAR |
| 2024-12-18 | 4 | Loew Caroline — Chief Executive Officer, Director | Sale (S): 2,763 @ $3.40 | EDGAR |
| 2024-11-08 | 4 | Goodman Vicki L — Chief Medical Officer | Sale (S): 5,069 @ $3.33 | EDGAR |
| 2024-11-01 | 4 | Cutler Adam D. — Chief Financial Officer | Sale (S): 7,421 @ $3.41 | EDGAR |
| 2024-09-23 | 4 | Minegishi Sachiyo — Director | Grant/award (A): 15,335 (derivative) @ $0 | EDGAR |
| 2024-08-15 | 4 | ALTSCHULLER Susan — Director | Purchase (P): 10,000 @ $3.21 | EDGAR |
| 2024-07-31 | 4 | Golumbeski George — Director | Grant/award (A): 15,334 (derivative) @ $0 | EDGAR |
| 2024-07-18 | 4 | Keson-Brookes Maiken — See Remarks | Sale (S): 2,157 @ $3.41 | EDGAR |
| 2024-07-08 | 4 | Loew Caroline — Chief Executive Officer, Director | Sale (S): 12,531 @ $2.91 | EDGAR |
| 2024-06-05 | 4/A | ALTSCHULLER Susan — Director | Grant/award (A): 8,462 (derivative) @ $0 | EDGAR |
| 2024-06-05 | 4/A | Hickey Benjamin — Director | Grant/award (A): 8,462 (derivative) @ $0 | EDGAR |
| 2024-06-05 | 4/A | Jackson Scott Thomas — Director | Grant/award (A): 8,462 (derivative) @ $0 | EDGAR |
| 2024-06-05 | 4/A | Cuss Francis M — Director | Grant/award (A): 8,462 (derivative) @ $0 | EDGAR |
| 2024-06-03 | 4 | ALTSCHULLER Susan — Director | Grant/award (A): 8,462 (derivative) @ $3.35 | EDGAR |
| 2024-06-03 | 4 | Hickey Benjamin — Director | Grant/award (A): 8,462 (derivative) @ $3.35 | EDGAR |
| 2024-06-03 | 4 | Jackson Scott Thomas — Director | Grant/award (A): 8,462 (derivative) @ $3.35 | EDGAR |
| 2024-06-03 | 4 | Cuss Francis M — Director | Grant/award (A): 8,462 (derivative) @ $3.35 | EDGAR |
| 2024-04-11 | 4/A | Loew Caroline — Chief Executive Officer, Director | Grant/award (A): 379,690 (derivative) | EDGAR |
| 2024-03-04 | 4 | Loew Caroline — Chief Executive Officer, Director | Grant/award (A): 48,475 @ $0 · Grant/award (A): 90,025 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Keson-Brookes Maiken — See Remarks | Grant/award (A): 16,800 @ $0 · Grant/award (A): 31,200 (derivative) @ $0 | EDGAR |
| 2023-12-18 | 4 | ALTSCHULLER Susan — Director | Grant/award (A): 15,021 (derivative) @ $0 | EDGAR |
| 2023-12-18 | 4 | Hickey Benjamin — Director | Grant/award (A): 15,021 (derivative) @ $0 | EDGAR |
| 2023-12-18 | 4 | Cutler Adam D. — Chief Financial Officer | Grant/award (A): 78,859 @ $0 · Grant/award (A): 146,452 (derivative) @ $0 | EDGAR |
| 2023-12-18 | 4 | Keson-Brookes Maiken — See Remarks | Grant/award (A): 29,207 @ $0 · Grant/award (A): 54,242 (derivative) @ $0 | EDGAR |
| 2023-12-18 | 4 | Jackson Scott Thomas — Director | Grant/award (A): 15,021 (derivative) @ $0 | EDGAR |
| 2023-12-18 | 4 | Cuss Francis M — Director | Grant/award (A): 15,021 (derivative) @ $0 | EDGAR |
Recent 8-K events — Mural Oncology plc
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-12-05 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-24 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
| 2025-08-20 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-12 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-04-15 | 8-K | ? 8.01 — Other Events | EDGAR |
| 2025-03-25 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-03-11 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-03-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-01-10 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MURA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →